Home News

News

Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Daiichi Sankyo and Gustave Roussy Sign Multi-year and Multi-study Adaptive Phase II Trial Collaboration

Daiichi Sankyo and Gustave Roussy have signed a multi-year, multi-study research collaboration for the ongoing development of DS-1062 and patritumab...

Proof-of-Concept: A Novel Strategy for the Production of Site-specific Antibody-drug Conjugates

Researchers of USC/University of Southern California‘s School of Pharmacy have engineered a new, faster way to develop ADCs.In a...
Featured Image: Multiple microscopic slides with stained blood smears, ready for testing. Courtesy: © Fotolia. Used with permission.

First Patients Dosed with Combination of Loncastuximab Tesirine + Ibrutinib in DLBCL and MCL

Diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are two distinct subtypes of non-Hodgkin lymphoma (NHL). These...
Conditionally Active Biologics (CAB)

BioAtla Raises $72.5 Million In Series D Financing to Advance CAB-AXL and CAB-ROR2 Clinical...

San Diego (California-) based BioAtla, a global clinical-stage biotechnology company developing Conditionally Active Biologic antibody therapeutics, confirmed that it...

First Patients Dosed in Phase II Trial with Trastuzumab Duocarmazine in HER2-expressing Endometrial Carcinoma

A first patient has started treatment in a Phase II study designed to evaluate the safety and efficacy of...

Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab Mafodotin in R/R...

The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive...

Immunomedics and Roche Expand Study Collaboration in First-line Metastatic Triple-negative Breast Cancer

Immunomedics and Roche have agreed to expand their clinical trial collaboration to evaluate sacituzumab govitecan-hziy (Trodelvy™), a Trop-2-directed antibody...

Revitope and Junshi Biosciences Sign Research Collaboration to Develop Next Generation Immunotherapies

Cambridge (MA) based Revitope Oncology, a biotechnology company advancing a new class of precision cancer immunotherapies, and Junshi Biosciences,...
Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

Trastuzumab Duocarmazine Selected to be part of a New Investigational Treatment Arm for the...

The Quantum Leap Healthcare Collaborative™, a 501c(3) charitable organization established as a collaboration between medical researchers at University of...

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in...

San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent...